Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

BACKGROUND: We evaluated candidate circulating serum cytokines, chemokines and growth factors in patients with locally/regionally advanced melanoma receiving neoadjuvant ipilimumab with toxicity and clinical outcome. METHODS: Patients were treated with ipilimumab (10 mg/kg IV every 3 weeks, 2 doses)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarhini, Ahmad A., Zahoor, Haris, Lin, Yan, Malhotra, Usha, Sander, Cindy, Butterfield, Lisa H., Kirkwood, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570556/
https://www.ncbi.nlm.nih.gov/pubmed/26380086
http://dx.doi.org/10.1186/s40425-015-0081-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570556/
https://www.ncbi.nlm.nih.gov/pubmed/26380086
http://dx.doi.org/10.1186/s40425-015-0081-1

Ejemplares similares